Developer docs
API playgroundTry for free, no card

Search company profiles

Kleva

Full company profile

uuid000c7vz

Namestring
Kleva
Legal namestring
KLEVA Pharmaceuticals S.A.
Websiteurl
kleva.gr
Company typeenum
Private
Founded yearint
1974
Descriptiontext

Kleva Pharmaceuticals S.A. is a privately held Greek pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1974 by George Th. Chronopoulos and headquartered in Acharnes, Greece, with a second manufacturing facility of 7,500 sq.m. in Polydendri. The company provides an integrated portfolio of pharmaceutical services spanning contract manufacturing across multiple dosage forms (tablets, capsules, sterile injectables, ophthalmics, semi-solids, liquids, nasal preparations, suppositories), research and development from initial formulation through CTD-format dossier compilation, technology transfer with gap analysis and scale-up, regulatory affairs support including marketing authorization lifecycle management, and pharmacovigilance. Kleva owns 190 marketing authorizations globally and exports 80 products across 30 countries in Europe, the Middle East, Asia, Africa, Australia, New Zealand, and CIS markets.

The company's revenue model is multi-stream: contract manufacturing fees for client products, professional services revenue for R&D, technology transfer, and regulatory affairs engagements, and licensing/dossier sales from its owned marketing authorizations (190 MAs globally). Production capacity exceeds 18 million boxes annually, including 300 million tablets, 25 million capsules, and 12 million sterile ampoules. The technology infrastructure includes two quality control laboratories (analytical and microbiological), advanced analytical instrumentation (HPLC, UV-VIS, FTIR, dissolution apparatus), an independent Tech Transfer Department, and a serialization/track-and-trace system compliant with FMD Global guidelines.

Kleva's go-to-market is B2B enterprise field sales combined with event-driven business development (e.g., CPHI Milan 2024) and direct outreach to pharmaceutical companies worldwide. The customer base consists of 50+ pharmaceutical company clients across 30 countries, served through distribution and licensing agreements, technology transfer, or co-development models. The company has shifted from a Greece-centric generic manufacturer to an export-oriented CDMO since 2012, and has secured recent regulatory milestones including MHRA approval for ophthalmic solutions (July 2025) and GMP certification for Plant B Polydendri (November 2024). Ownership remains concentrated within the founding Chronopoulos family across three generations, with no disclosed external institutional or private equity investors.

Short descriptiontext

Kleva Pharmaceuticals S.A. is a Greek pharmaceutical CDMO founded in 1974, providing contract manufacturing, R&D, regulatory affairs, and technology transfer services across multiple dosage forms for pharmaceutical companies in 30 countries. It owns 190 marketing authorizations and operates EU GMP- and MHRA-certified facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersAthens, Greece
HQ citystring
Athens
HQ countrystring
Greece
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, pharmaceutical product development, generic drug manufacturing, pharmaceutical technology transfer, regulatory affairs services
Industry1 code
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Contract Manufacturing and Development (CDMO)
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Kleva manufactures pharmaceutical products on behalf of clients worldwide, providing production services across multiple dosage forms from its GMP-compliant facilities. Revenue is generated through manufacturing fees for client products.

kleva.gr
2Research & Development Services
TypeProfessional Services
Description

R&D services for third parties including development of generic pharmaceutical products from initial stages to CTD-format dossier compilation. Services include patent search, API sourcing, formulation development, and regulatory dossier preparation.

kleva.gr
3Technology Transfer Services
TypeProfessional Services
Description

Technology transfer services including review of registered product documentation, gap analysis, process transition between development and manufacturing sites, scale-up batch production, and stability testing.

kleva.gr
4Regulatory Affairs Services
TypeProfessional Services
Description

Regulatory affairs services including marketing authorization lifecycle management, registration procedures (National, DCP, MRP), dossier compilation in CTD/eCTD format, and regulatory support for product approvals.

kleva.gr
5Product Licensing and Dossier Sales
TypeLicensing Royalties
Description

Sale of marketing authorizations and dossiers, out-licensing activity providing upgraded CTD files aligned with European guidelines. The company owns 190 marketing authorizations globally.

kleva.gr
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Ezipol
Description

A leading product (Omeprazole) distributed in the Greek pharmaceutical market through a partner distribution channel.

kleva.gr
Core offering1 text field

Kleva is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from product development through commercial manufacturing. Its service portfolio includes contract manufacturing across multiple dosage forms (tablets, capsules, sterile injectables, ophthalmics, creams, ointments, liquids, suppositories, nasals), R&D and CTD-format dossier development, technology and analytical transfer, regulatory affairs, quality assurance, and pharmacovigilance. The company also owns 190 marketing authorizations globally and exports 80 products to regulated and non-regulated markets via licensing and distribution partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 50+ customers across 30 countries served since 2012
+4 more records
Product overview1 text field

Kleva Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) established in 1974, based in Athens, Greece. The company operates two manufacturing facilities and offers an integrated portfolio of products and services. Its core product offerings span multiple dosage forms including solid forms (tablets, capsules, granules), semi-solids (creams, ointments, gels), liquids (syrups, solutions), nasal preparations, parenterals (vials, ampules), suppositories, and ophthalmic products. Flagship product Ezipol (Omeprazole) represents their leading pharmaceutical formulation. The service portfolio includes contract manufacturing, R&D development services, regulatory affairs, technology transfer, quality assurance, pharmacovigilance, and international business development. With 190 marketing authorizations globally and operations across 30 countries, Kleva serves as a full-service pharmaceutical CDMO partner for clients in Europe, Asia, Africa, Oceania, and the Middle East.

Product and service8 records
1Contract Manufacturing Services
CategoryCDMO / Contract Manufacturing
Description

Full-service pharmaceutical contract development and manufacturing (CDMO) for client products across solid, semi-solid, liquid, nasal, parenteral, suppository, and ophthalmic dosage forms, covering product development, manufacturing, packaging, and release for pharmaceutical, nutraceutical, food supplement, medical device, and health & beauty clients.

2R&D Development Services
CategoryPharmaceutical R&D / Product Development
Description

Complete generic pharmaceutical product development services from initial stages through CTD-format dossier compilation, including patent search, API sourcing, formulation development, pilot scale batches, and stability studies for third-party clients.

3Regulatory Affairs Services
CategoryRegulatory Affairs
Description

Comprehensive regulatory services including marketing authorization applications, dossier compilation in CTD/eCTD format, regulatory support for product approvals, renewals, and variations across EU and non-EU countries, including National, DCP, and MRP registration procedures.

4Technology Transfer Services
CategoryTechnology Transfer
Description

Comprehensive technology transfer services including review of registered product documentation, gap analysis, process optimization between development and manufacturing sites, scale-up batch production, and stability testing.

5Quality Assurance Services
CategoryQuality Assurance
Description

Quality management services ensuring compliance with EU GMP, ISO 9001:2015, and international regulatory requirements, delivered through continuous monitoring, improvement programs, and trained scientific personnel.

6Pharmacovigilance Services
CategoryPharmacovigilance
Description

Comprehensive pharmacovigilance system ensuring compliance with international, EU, and local legal requirements, including 24/7 adverse event reporting lines and a permanently available Qualified Person (QPPV).

7Business Development and Licensing Services
CategoryBusiness Development / Licensing
Description

International business development including market strategy, distribution agreements, licensing, dossier sales, and co-development partnerships for Kleva's 190 owned marketing authorizations across 30 countries.

8Ezipol (Omeprazole)
CategoryBranded Pharmaceutical Product
Description

Branded pharmaceutical product (Omeprazole) — Kleva's flagship proprietary formulation — distributed in the Greek pharmaceutical market through partner distribution channels for healthcare professionals and patients.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Afidnes Forest Protection Volunteer Association
Strategic tierMinorTypeOthersAnnounced on2024-01-01
Description

Third consecutive year of symbolic financial contribution to volunteer fire prevention and civil protection association. The association operates 24-hour shifts during fire season for fire prevention, extreme weather response, and rescues.

kleva.gr
2Ezipol Distribution Partner (Greece)
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2023-12-27
Description

New collaboration for distribution of Ezipol/Omeprazole product in the Greek pharmaceutical market. Ezipol is distributed through partner's distribution channel, making the product available to healthcare professionals and patients in Greece.

kleva.gr
3Greek Red Cross
Strategic tierMinorTypeOthersAnnounced on2023-02-23
Description

Humanitarian partnership for earthquake relief. Collected essential supplies for earthquake victims in Turkey and Syria, delivered to Red Cross facilities on February 23, 2023.

kleva.gr
Strategic tierMinorTypeOthersAnnounced on2023-01-24
Description

Donation of five fully integrated computer units to the Pharmaceutical Department of the Center of Continuing Education and Lifelong Learning at NKUA, in memory of founder George Chronopoulos.

5Actavis, Sandoz, Pliva, Nycomed
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2005-01-01
Description

Global pharmaceutical companies including Actavis, Sandoz, Pliva, and Nycomed partnered with Kleva through Business Development Department established in 2005 for export expansion.

kleva.gr
6Vigi-Care
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmacovigilance partner providing 24/7 safety reporting line (Tel: +30 217 000 9002) and email (safety@vigi-care.eu) for adverse event reporting related to Kleva products.

kleva.gr
7Creative Pharmaceutical Services
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmacovigilance partner committed to complying with laws governing operation, maintaining good practices, and providing high-quality services. Contact: Tel: +30 210 3259365 (24h), pv@creativephs.com.

kleva.gr
Recent move17 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

France-based CDMO with broad sterile, liquid, and solid-dose capabilities serving European generic and branded pharma. Comparable service breadth and customer overlap with Kleva.

TypeDirect peer
Description

German-headquartered CDMO offering solid, semi-solid, liquid, and sterile dosage forms for generics and branded pharma across Europe. Comparable to Kleva in business model (contract development + manufacturing + regulatory dossiers) and customer base (European generic pharma sponsors).

TypeBroad incumbent
Description

Global, multi-modality CDMO with extensive sterile fill-finish, oral solid, and inhalation capacity. A much larger incumbent that competes with Kleva on European tech-transfer and commercial manufacturing contracts, particularly with innovator sponsors.

TypeBroad incumbent
Description

Global CDMO with sterile injectable and oral solid dose capacity including European sites. Competes with Kleva for European commercial manufacturing and tech-transfer programs for generic and specialty pharma.

TypeBroad incumbent
Description

European CDMO with capabilities across peptides, small molecules, injectables, and oral solids. Overlaps with Kleva in sterile and oral dosage forms for generic and branded pharma clients.

6Fareva
TypeDirect peer
Description

French pharmaceutical CDMO with development, manufacturing, and packaging services across multiple dosage forms. Operates as a multi-site EU alternative for generic and branded pharma sponsors similar to Kleva.

TypeRegional player
Description

Bulgarian pharmaceutical manufacturer with generics, contract manufacturing, and dossier licensing activities in CEE and CIS. Comparable Eastern-European generics manufacturer with similar dossier/CMO business model.

TypeBroad incumbent
Description

Northern Ireland-headquartered CDMO offering API, formulation development, commercial manufacturing, and regulatory services. Comparable integrated CDMO model and target customer base across Europe and the US.

9Recipharm
TypeDirect peer
Description

Swedish CDMO specializing in solid dose, sterile fill-finish, and inhalation products for generics and innovators. Closely comparable multi-dosage-form EU CDMO serving a similar pharma client base.

TypeDirect peer
Description

Portuguese CDMO with integrated drug substance, drug product, and analytical services. Comparable full-service CDMO model though more oriented to complex/API work; competes for European tech-transfer and commercial manufacturing mandates.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kleva

Pharmaceutical Contract Manufacturing and Development (CDMO)kleva.gr

Kleva Pharmaceuticals S.A. is a Greek pharmaceutical CDMO founded in 1974, providing contract manufacturing, R&D, regulatory affairs, and technology transfer services across multiple dosage forms for pharmaceutical companies in 30 countries. It owns 190 marketing authorizations and operates EU GMP- and MHRA-certified facilities.

What Kleva does

Kleva Pharmaceuticals S.A. is a privately held Greek pharmaceutical Contract Development and Manufacturing Organization (CDMO) founded in 1974 by George Th. Chronopoulos and headquartered in Acharnes, Greece, with a second manufacturing facility of 7,500 sq.m. in Polydendri. The company provides an integrated portfolio of pharmaceutical services spanning contract manufacturing across multiple dosage forms (tablets, capsules, sterile injectables, ophthalmics, semi-solids, liquids, nasal preparations, suppositories), research and development from initial formulation through CTD-format dossier compilation, technology transfer with gap analysis and scale-up, regulatory affairs support including marketing authorization lifecycle management, and pharmacovigilance. Kleva owns 190 marketing authorizations globally and exports 80 products across 30 countries in Europe, the Middle East, Asia, Africa, Australia, New Zealand, and CIS markets.

The company's revenue model is multi-stream: contract manufacturing fees for client products, professional services revenue for R&D, technology transfer, and regulatory affairs engagements, and licensing/dossier sales from its owned marketing authorizations (190 MAs globally). Production capacity exceeds 18 million boxes annually, including 300 million tablets, 25 million capsules, and 12 million sterile ampoules. The technology infrastructure includes two quality control laboratories (analytical and microbiological), advanced analytical instrumentation (HPLC, UV-VIS, FTIR, dissolution apparatus), an independent Tech Transfer Department, and a serialization/track-and-trace system compliant with FMD Global guidelines.

Kleva's go-to-market is B2B enterprise field sales combined with event-driven business development (e.g., CPHI Milan 2024) and direct outreach to pharmaceutical companies worldwide. The customer base consists of 50+ pharmaceutical company clients across 30 countries, served through distribution and licensing agreements, technology transfer, or co-development models. The company has shifted from a Greece-centric generic manufacturer to an export-oriented CDMO since 2012, and has secured recent regulatory milestones including MHRA approval for ophthalmic solutions (July 2025) and GMP certification for Plant B Polydendri (November 2024). Ownership remains concentrated within the founding Chronopoulos family across three generations, with no disclosed external institutional or private equity investors.

Kleva firmographics

Firmographics
Name
Kleva
Legal name
KLEVA Pharmaceuticals S.A.
Website
https://kleva.gr
Company type
Private
Founded year
1974
Operating status
Operating
Headcount range
101–250 employees
Short description
Kleva Pharmaceuticals S.A. is a Greek pharmaceutical CDMO founded in 1974, providing contract manufacturing, R&D, regulatory affairs, and technology transfer services across multiple dosage forms for pharmaceutical companies in 30 countries. It owns 190 marketing authorizations and operates EU GMP- and MHRA-certified facilities.
Ownership category
akta.pro rank

Kleva industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing and Development (CDMO)
NAICS
Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical manufacturing
  • Pharmaceutical product development
  • Generic drug manufacturing
  • Pharmaceutical technology transfer
  • Regulatory affairs services

Where Kleva is headquartered

Location

Headquarters

HQ city
Athens
HQ country
Greece
HQ region
Europe

Offices3 records

Markets served

Kleva business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Manufacturing Services: Kleva manufactures pharmaceutical products on behalf of clients worldwide, providing production services across multiple dosage forms from its GMP-compliant facilities. Revenue is generated through manufacturing fees for client products.
  2. Research & Development Services: R&D services for third parties including development of generic pharmaceutical products from initial stages to CTD-format dossier compilation. Services include patent search, API sourcing, formulation development, and regulatory dossier preparation.
  3. Technology Transfer Services: Technology transfer services including review of registered product documentation, gap analysis, process transition between development and manufacturing sites, scale-up batch production, and stability testing.
  4. Regulatory Affairs Services: Regulatory affairs services including marketing authorization lifecycle management, registration procedures (National, DCP, MRP), dossier compilation in CTD/eCTD format, and regulatory support for product approvals.
  5. Product Licensing and Dossier Sales: Sale of marketing authorizations and dossiers, out-licensing activity providing upgraded CTD files aligned with European guidelines. The company owns 190 marketing authorizations globally.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Kleva product offering

Product offering

Core offering

Kleva is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from product development through commercial manufacturing. Its service portfolio includes contract manufacturing across multiple dosage forms (tablets, capsules, sterile injectables, ophthalmics, creams, ointments, liquids, suppositories, nasals), R&D and CTD-format dossier development, technology and analytical transfer, regulatory affairs, quality assurance, and pharmacovigilance. The company also owns 190 marketing authorizations globally and exports 80 products to regulated and non-regulated markets via licensing and distribution partnerships.

Product overview

Kleva Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) established in 1974, based in Athens, Greece. The company operates two manufacturing facilities and offers an integrated portfolio of products and services. Its core product offerings span multiple dosage forms including solid forms (tablets, capsules, granules), semi-solids (creams, ointments, gels), liquids (syrups, solutions), nasal preparations, parenterals (vials, ampules), suppositories, and ophthalmic products. Flagship product Ezipol (Omeprazole) represents their leading pharmaceutical formulation. The service portfolio includes contract manufacturing, R&D development services, regulatory affairs, technology transfer, quality assurance, pharmacovigilance, and international business development. With 190 marketing authorizations globally and operations across 30 countries, Kleva serves as a full-service pharmaceutical CDMO partner for clients in Europe, Asia, Africa, Oceania, and the Middle East.

Differentiator

Problem solved

Functional benefit

Brands

  • Ezipol: A leading product (Omeprazole) distributed in the Greek pharmaceutical market through a partner distribution channel.

Products and services

  • Contract Manufacturing Services Full-service pharmaceutical contract development and manufacturing (CDMO) for client products across solid, semi-solid, liquid, nasal, parenteral, suppository, and ophthalmic dosage forms, covering product development, manufacturing, packaging, and release for pharmaceutical, nutraceutical, food supplement, medical device, and health & beauty clients.
  • R&D Development Services Complete generic pharmaceutical product development services from initial stages through CTD-format dossier compilation, including patent search, API sourcing, formulation development, pilot scale batches, and stability studies for third-party clients.
  • Regulatory Affairs Services Comprehensive regulatory services including marketing authorization applications, dossier compilation in CTD/eCTD format, regulatory support for product approvals, renewals, and variations across EU and non-EU countries, including National, DCP, and MRP registration procedures.
  • Technology Transfer Services Comprehensive technology transfer services including review of registered product documentation, gap analysis, process optimization between development and manufacturing sites, scale-up batch production, and stability testing.
  • Quality Assurance Services Quality management services ensuring compliance with EU GMP, ISO 9001:2015, and international regulatory requirements, delivered through continuous monitoring, improvement programs, and trained scientific personnel.
  • Pharmacovigilance Services Comprehensive pharmacovigilance system ensuring compliance with international, EU, and local legal requirements, including 24/7 adverse event reporting lines and a permanently available Qualified Person (QPPV).
  • Business Development and Licensing Services International business development including market strategy, distribution agreements, licensing, dossier sales, and co-development partnerships for Kleva's 190 owned marketing authorizations across 30 countries.
  • Ezipol (Omeprazole) Branded pharmaceutical product (Omeprazole) — Kleva's flagship proprietary formulation — distributed in the Greek pharmaceutical market through partner distribution channels for healthcare professionals and patients.

Quantifiable outcome

  • 50+ customers across 30 countries served since 2012
  • +4 more outcomes

Companies that use Kleva

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Kleva technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kleva partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered minor, major and core.

  • Afidnes Forest Protection Volunteer AssociationminorOthers · 1 January 2024Third consecutive year of symbolic financial contribution to volunteer fire prevention and civil protection association. The association operates 24-hour shifts during fire season for fire prevention, extreme weather response, and rescues.
  • Ezipol Distribution Partner (Greece)minorChannel Partner/ Reseller/ Distributor · 27 December 2023New collaboration for distribution of Ezipol/Omeprazole product in the Greek pharmaceutical market. Ezipol is distributed through partner's distribution channel, making the product available to healthcare professionals and patients in Greece.
  • Greek Red CrossminorOthers · 23 February 2023Humanitarian partnership for earthquake relief. Collected essential supplies for earthquake victims in Turkey and Syria, delivered to Red Cross facilities on February 23, 2023.
  • National and Kapodistrian University of Athens - Pharmaceutical DepartmentminorOthers · 24 January 2023Donation of five fully integrated computer units to the Pharmaceutical Department of the Center of Continuing Education and Lifelong Learning at NKUA, in memory of founder George Chronopoulos.
  • Actavis, Sandoz, Pliva, NycomedmajorStrategic or Co-development Partner · 1 January 2005Global pharmaceutical companies including Actavis, Sandoz, Pliva, and Nycomed partnered with Kleva through Business Development Department established in 2005 for export expansion.
  • Vigi-CarecoreStrategic or Co-development PartnerPharmacovigilance partner providing 24/7 safety reporting line (Tel: +30 217 000 9002) and email (safety@vigi-care.eu) for adverse event reporting related to Kleva products.
  • Creative Pharmaceutical ServicescoreStrategic or Co-development PartnerPharmacovigilance partner committed to complying with laws governing operation, maintaining good practices, and providing high-quality services. Contact: Tel: +30 210 3259365 (24h), pv@creativephs.com.

Scale indicators10 records

Recent moves17 records

Expansion highlights5 records

Kleva competitors and assessment

Company assessment

Direct peers

  • Delpharm: France-based CDMO with broad sterile, liquid, and solid-dose capabilities serving European generic and branded pharma. Comparable service breadth and customer overlap with Kleva.
  • Aenova Group: German-headquartered CDMO offering solid, semi-solid, liquid, and sterile dosage forms for generics and branded pharma across Europe. Comparable to Kleva in business model (contract development + manufacturing + regulatory dossiers) and customer base (European generic pharma sponsors).
  • Fareva: French pharmaceutical CDMO with development, manufacturing, and packaging services across multiple dosage forms. Operates as a multi-site EU alternative for generic and branded pharma sponsors similar to Kleva.
  • Recipharm: Swedish CDMO specializing in solid dose, sterile fill-finish, and inhalation products for generics and innovators. Closely comparable multi-dosage-form EU CDMO serving a similar pharma client base.
  • Hovione: Portuguese CDMO with integrated drug substance, drug product, and analytical services. Comparable full-service CDMO model though more oriented to complex/API work; competes for European tech-transfer and commercial manufacturing mandates.

Broad incumbents

  • Catalent: Global, multi-modality CDMO with extensive sterile fill-finish, oral solid, and inhalation capacity. A much larger incumbent that competes with Kleva on European tech-transfer and commercial manufacturing contracts, particularly with innovator sponsors.
  • Piramal Pharma Solutions: Global CDMO with sterile injectable and oral solid dose capacity including European sites. Competes with Kleva for European commercial manufacturing and tech-transfer programs for generic and specialty pharma.
  • CordenPharma: European CDMO with capabilities across peptides, small molecules, injectables, and oral solids. Overlaps with Kleva in sterile and oral dosage forms for generic and branded pharma clients.
  • Almac Group: Northern Ireland-headquartered CDMO offering API, formulation development, commercial manufacturing, and regulatory services. Comparable integrated CDMO model and target customer base across Europe and the US.

Regional players

  • Sopharma: Bulgarian pharmaceutical manufacturer with generics, contract manufacturing, and dossier licensing activities in CEE and CIS. Comparable Eastern-European generics manufacturer with similar dossier/CMO business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Kleva compliance and trust

Trust signal

Compliance5 records

Kleva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kleva leadership team

Management profile

Number of profiles

Profiles3 records

Kleva funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kleva M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kleva

What does Kleva do?

Kleva is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from product development through commercial manufacturing. Its service portfolio includes contract manufacturing across multiple dosage forms (tablets, capsules, sterile injectables, ophthalmics, creams, ointments, liquids, suppositories, nasals), R&D and CTD-format dossier development, technology and analytical transfer, regulatory affairs, quality assurance, and pharmacovigilance. The company also owns 190 marketing authorizations globally and exports 80 products to regulated and non-regulated markets via licensing and distribution partnerships.

Is Kleva a public or private company?

Kleva is a private company. It is classified as family owned and is currently operating.

When was Kleva founded?

Kleva was founded in 1974. It employs 101 to 250 people.

Where is Kleva based?

Kleva is headquartered in Athens, Greece, in the Europe region.

How does Kleva make money?

Five revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are research & Development Services, technology Transfer Services, regulatory Affairs Services and product Licensing and Dossier Sales.

Who are Kleva's main competitors?

Direct peers on record are Delpharm, Aenova Group, Fareva, Recipharm and Hovione. Broad incumbents are Catalent, Piramal Pharma Solutions, CordenPharma and Almac Group. Sopharma is listed as a regional player.

Does Kleva have an API?

No public API is recorded for Kleva.

What industry is Kleva in?

Kleva's product category is Pharmaceutical Contract Manufacturing and Development (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 424210 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales